These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 19999808)

  • 1. [Hyperhomocysteinemia and the disturbance of haemostasis--facts and mythes].
    Malinowska J; Nowak P; Olas B
    Pol Merkur Lekarski; 2009 Nov; 27(161):413-8. PubMed ID: 19999808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The disturbance of hemostasis induced by hyperhomocysteinemia; the role of antioxidants.
    Malinowska J; Kolodziejczyk J; Olas B
    Acta Biochim Pol; 2012; 59(2):185-94. PubMed ID: 22577622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanism of action of homocysteine and its thiolactone in hemostasis system.
    Karolczak K; Olas B
    Physiol Res; 2009; 58(5):623-633. PubMed ID: 19093716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effect of homocysteine in the reduced form, its thiolactone and protein homocysteinylation on hemostatic properties of plasma.
    Malinowska J; Nowak P; Olas B
    Thromb Res; 2011 Mar; 127(3):214-9. PubMed ID: 21186049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of biological properties of selected elements of haemostasis after treatment with the oxidized form of homocysteine in vitro.
    Malinowska J; Olas B
    Platelets; 2011; 22(8):629-32. PubMed ID: 21627409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aronia melanocarpa extract suppresses the biotoxicity of homocysteine and its metabolite on the hemostatic activity of fibrinogen and plasma.
    Malinowska J; Babicz K; Olas B; Stochmal A; Oleszek W
    Nutrition; 2012 Jul; 28(7-8):793-8. PubMed ID: 22261575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
    Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
    Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Homocysteine and its thiolactone may promote apoptotic events in blood platelets in vitro.
    Olas B; Malinowska J; Rywaniak J
    Platelets; 2010; 21(7):533-40. PubMed ID: 20701459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Homocysteine and its thiolactone-mediated modification of fibrinogen affect blood platelet adhesion.
    Malinowska J; Olas B
    Platelets; 2012; 23(5):409-12. PubMed ID: 22010991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Molecular mechanisms of biotoxicity of homocysteine--facts and hypotheses].
    Turski WA; Bald E
    Postepy Biochem; 2005; 51(4):395-406. PubMed ID: 16676574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of resveratrol on hemostatic properties of human fibrinogen and plasma during model of hyperhomocysteinemia.
    Malinowska J; Olas B
    Thromb Res; 2010 Nov; 126(5):e379-82. PubMed ID: 20869101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pathophysiological hypothesis of homocysteine thiolactone-mediated vascular disease.
    Jakubowski H
    J Physiol Pharmacol; 2008 Dec; 59 Suppl 9():155-67. PubMed ID: 19261978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New cardiovascular risk factors: homocysteine and vitamins involved in homocysteine metabolism.
    De Caterina R; Zampolli A; Madonna R; Fioretti P; Vanuzzo D
    Ital Heart J; 2004 Jun; 5 Suppl 6():19S-24S. PubMed ID: 15185912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response of blood platelets to resveratrol during a model of hyperhomocysteinemia.
    Malinowska J; Olas B
    Platelets; 2011; 22(4):277-83. PubMed ID: 21557714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Homocysteine metabolism and risk of cardiovascular diseases: importance of the nutritional status on folic acid, vitamins B6 and B12].
    Alemán G; Tovar AR; Torres N
    Rev Invest Clin; 2001; 53(2):141-51. PubMed ID: 11421110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Homocysteine and hyperhomocysteinemia].
    Laskowska-Klita T
    Pol Merkur Lekarski; 2001 Mar; 10(57):135-7. PubMed ID: 11398509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. May modifications of human plasma proteins stimulated by homocysteine and its thiolactone induce changes of hemostatic function of plasma in vitro?
    Olas B; Kołodziejczyk J; Malinowska J
    Gen Physiol Biophys; 2010 Jun; 29(2):186-93. PubMed ID: 20577030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homocysteinylated fibrinogen forms disulfide-linked complexes with albumin.
    Sauls DL; Warren M; Hoffman M
    Thromb Res; 2011 Jun; 127(6):576-81. PubMed ID: 21316742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperhomocysteinemia: an additional cardiovascular risk factor.
    Fanapour PC; Yug B; Kochar MS
    WMJ; 1999 Dec; 98(8):51-4. PubMed ID: 10639897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Homocysteine. The cardiovascular risk factor of the next millennium?].
    Suárez García I; Gómez Cerezo JF; Ríos Blanco JJ; Barbado Hernández FJ; Vázquez Rodríguez JJ
    An Med Interna; 2001 Apr; 18(4):211-7. PubMed ID: 11496543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.